An observational study of the occurrence of serious adverse reactions among patients who receive optison in routine medical practice

Kevin Wei, Sangeeta Shah, Wael A. Jaber, Anthony DeMaria

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

METHODS: Patients referred for routine rest or stress two-dimensional echocardiography who had indications for contrast were enrolled. Vital signs were obtained at baseline and at intervals up to 1 hour after dosing of Optison. Patients were followed for the development of any serious adverse event (SAE), defined as an event that causes death, is life threatening, requires or prolongs hospitalization, or causes another important event, for 24 hours after Optison administration.

RESULTS: A total of 1,039 patients were enrolled, and 76% had 24-hour follow-up. The median age was 60 years (range, 20-97 years), and 62% were men. The mean body mass index was 33 ± 9 kg/m(2). Patient comorbidities included hypertension (73%), hyperlipidemia (64%), smoking (52%), and diabetes (37%). There were significant increases in systolic blood pressure, heart rate, and respiratory rate between the baseline, 5- to 15-min, 30-min, and 60-min time points after the administration of Optison in patients undergoing stress studies but none in those undergoing rest studies. There was a total of six SAEs during the study, which were felt to be related not to Optison but rather to the stress test itself or to the patient's underlying pathology. Although two events were classified as SAEs because of hospitalization, the hospitalizations were appropriate for pathology that would have been missed without Optison use.

CONCLUSIONS: In this large, prospective safety study of Optison during routine resting and stress echocardiography, no SAEs related to Optison developed. Optison helped define abnormalities that required appropriate hospitalization for further management.

BACKGROUND: Reports of ultrasound contrast agent safety have been derived mainly from retrospective databases rather than from studies specifically designed to assess safety. The purpose of this study was to prospectively determine the safety of Optison (GE Healthcare, Princeton, NJ) in routine medical practice.

Original languageEnglish (US)
Pages (from-to)1006-1010
Number of pages5
JournalJournal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
Volume27
Issue number9
DOIs
StatePublished - Sep 1 2014
Externally publishedYes

Fingerprint

Observational Studies
Hospitalization
Safety
Pathology
Blood Pressure
FS 069
Stress Echocardiography
Vital Signs
Respiratory Rate
Hyperlipidemias
Exercise Test
Contrast Media
Echocardiography
Comorbidity
Cause of Death
Body Mass Index
Heart Rate
Smoking
Databases
Prospective Studies

Keywords

  • Contrast agents
  • Echocardiography
  • Safety

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

@article{47f4ac0ca18740819cd340e7604c2b42,
title = "An observational study of the occurrence of serious adverse reactions among patients who receive optison in routine medical practice",
abstract = "METHODS: Patients referred for routine rest or stress two-dimensional echocardiography who had indications for contrast were enrolled. Vital signs were obtained at baseline and at intervals up to 1 hour after dosing of Optison. Patients were followed for the development of any serious adverse event (SAE), defined as an event that causes death, is life threatening, requires or prolongs hospitalization, or causes another important event, for 24 hours after Optison administration.RESULTS: A total of 1,039 patients were enrolled, and 76{\%} had 24-hour follow-up. The median age was 60 years (range, 20-97 years), and 62{\%} were men. The mean body mass index was 33 ± 9 kg/m(2). Patient comorbidities included hypertension (73{\%}), hyperlipidemia (64{\%}), smoking (52{\%}), and diabetes (37{\%}). There were significant increases in systolic blood pressure, heart rate, and respiratory rate between the baseline, 5- to 15-min, 30-min, and 60-min time points after the administration of Optison in patients undergoing stress studies but none in those undergoing rest studies. There was a total of six SAEs during the study, which were felt to be related not to Optison but rather to the stress test itself or to the patient's underlying pathology. Although two events were classified as SAEs because of hospitalization, the hospitalizations were appropriate for pathology that would have been missed without Optison use.CONCLUSIONS: In this large, prospective safety study of Optison during routine resting and stress echocardiography, no SAEs related to Optison developed. Optison helped define abnormalities that required appropriate hospitalization for further management.BACKGROUND: Reports of ultrasound contrast agent safety have been derived mainly from retrospective databases rather than from studies specifically designed to assess safety. The purpose of this study was to prospectively determine the safety of Optison (GE Healthcare, Princeton, NJ) in routine medical practice.",
keywords = "Contrast agents, Echocardiography, Safety",
author = "Kevin Wei and Sangeeta Shah and Jaber, {Wael A.} and Anthony DeMaria",
year = "2014",
month = "9",
day = "1",
doi = "10.1016/j.echo.2014.04.020",
language = "English (US)",
volume = "27",
pages = "1006--1010",
journal = "Journal of the American Society of Echocardiography",
issn = "0894-7317",
publisher = "Mosby Inc.",
number = "9",

}

TY - JOUR

T1 - An observational study of the occurrence of serious adverse reactions among patients who receive optison in routine medical practice

AU - Wei, Kevin

AU - Shah, Sangeeta

AU - Jaber, Wael A.

AU - DeMaria, Anthony

PY - 2014/9/1

Y1 - 2014/9/1

N2 - METHODS: Patients referred for routine rest or stress two-dimensional echocardiography who had indications for contrast were enrolled. Vital signs were obtained at baseline and at intervals up to 1 hour after dosing of Optison. Patients were followed for the development of any serious adverse event (SAE), defined as an event that causes death, is life threatening, requires or prolongs hospitalization, or causes another important event, for 24 hours after Optison administration.RESULTS: A total of 1,039 patients were enrolled, and 76% had 24-hour follow-up. The median age was 60 years (range, 20-97 years), and 62% were men. The mean body mass index was 33 ± 9 kg/m(2). Patient comorbidities included hypertension (73%), hyperlipidemia (64%), smoking (52%), and diabetes (37%). There were significant increases in systolic blood pressure, heart rate, and respiratory rate between the baseline, 5- to 15-min, 30-min, and 60-min time points after the administration of Optison in patients undergoing stress studies but none in those undergoing rest studies. There was a total of six SAEs during the study, which were felt to be related not to Optison but rather to the stress test itself or to the patient's underlying pathology. Although two events were classified as SAEs because of hospitalization, the hospitalizations were appropriate for pathology that would have been missed without Optison use.CONCLUSIONS: In this large, prospective safety study of Optison during routine resting and stress echocardiography, no SAEs related to Optison developed. Optison helped define abnormalities that required appropriate hospitalization for further management.BACKGROUND: Reports of ultrasound contrast agent safety have been derived mainly from retrospective databases rather than from studies specifically designed to assess safety. The purpose of this study was to prospectively determine the safety of Optison (GE Healthcare, Princeton, NJ) in routine medical practice.

AB - METHODS: Patients referred for routine rest or stress two-dimensional echocardiography who had indications for contrast were enrolled. Vital signs were obtained at baseline and at intervals up to 1 hour after dosing of Optison. Patients were followed for the development of any serious adverse event (SAE), defined as an event that causes death, is life threatening, requires or prolongs hospitalization, or causes another important event, for 24 hours after Optison administration.RESULTS: A total of 1,039 patients were enrolled, and 76% had 24-hour follow-up. The median age was 60 years (range, 20-97 years), and 62% were men. The mean body mass index was 33 ± 9 kg/m(2). Patient comorbidities included hypertension (73%), hyperlipidemia (64%), smoking (52%), and diabetes (37%). There were significant increases in systolic blood pressure, heart rate, and respiratory rate between the baseline, 5- to 15-min, 30-min, and 60-min time points after the administration of Optison in patients undergoing stress studies but none in those undergoing rest studies. There was a total of six SAEs during the study, which were felt to be related not to Optison but rather to the stress test itself or to the patient's underlying pathology. Although two events were classified as SAEs because of hospitalization, the hospitalizations were appropriate for pathology that would have been missed without Optison use.CONCLUSIONS: In this large, prospective safety study of Optison during routine resting and stress echocardiography, no SAEs related to Optison developed. Optison helped define abnormalities that required appropriate hospitalization for further management.BACKGROUND: Reports of ultrasound contrast agent safety have been derived mainly from retrospective databases rather than from studies specifically designed to assess safety. The purpose of this study was to prospectively determine the safety of Optison (GE Healthcare, Princeton, NJ) in routine medical practice.

KW - Contrast agents

KW - Echocardiography

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=85027941819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027941819&partnerID=8YFLogxK

U2 - 10.1016/j.echo.2014.04.020

DO - 10.1016/j.echo.2014.04.020

M3 - Article

C2 - 24930121

AN - SCOPUS:85027941819

VL - 27

SP - 1006

EP - 1010

JO - Journal of the American Society of Echocardiography

JF - Journal of the American Society of Echocardiography

SN - 0894-7317

IS - 9

ER -